Live Breaking News & Updates on Dependent Chronic Graft Vs Host Disease

Stay updated with breaking news from Dependent chronic graft vs host disease. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Novartis Pharma AG: New data at ASH spotlight Novartis recently approved Scemblix, next-generation CAR-T platform and expanding hematology portfolio

New longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix (asciminib) in patients with PH+ CML-CPEarly findings from YTB323 and PHE885 CAR-T cell therapies ....

United States , Isabella Zinck , Thomas Hungerbuehler , Susanne Schaffert , Samir Shah , Parag Mahanti , Julie Masow , Sloan Simpson , Promacta Revolade , Alina Levchuk , Drug Administration , Incyte Corporation As Jakafi , Novartis Us External Communications , Novartis External Communications , Exchange Commission , American Society Of Hematology , Novartis Hematology Communications , Incyte Corporation , American Society , Annual Meeting , First In Human Study , Charge Platform , Diffuse Largeb Cell Lymphoma , Fully Human , Refractory Multiple Myeloma Manufactured , Malignant Hematology ,

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio

Investegate announcements from NOVARTIS AG CHF0.50(REGD), New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio ....

United States , Isabella Zinck , Thomas Hungerbuehler , Susanne Schaffert , Samir Shah , Parag Mahanti , Julie Masow , Sloan Simpson , Promacta Revolade , Alina Levchuk , Drug Administration , Incyte Corporation As Jakafi , Novartis Us External Communications , Novartis External Communications , Exchange Commission , American Society Of Hematology , Novartis Hematology Communications , Incyte Corporation , American Society , Annual Meeting , First In Human Study , Diffuse Largeb Cell Lymphoma , Fully Human , Refractory Multiple Myeloma Manufactured , Malignant Hematology , Combination With Hypomethylating Agents ,

More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition

Numerous oral presentations highlighting data for tafasitamab, parsaclisib, ruxolitinib, pemigatinib, itacitinib and ponatinib to be highlighted during the Congress Incyte (Nasdaq:INCY) today announced ....

United States , United Kingdom , Catalina Loveman , Peter Langmuir , Ponatinib Iclusig , Tafasitamab Lenalidomide , Christine Chiou , American Society Of Hematology Annual Meeting , Xencor Inc , Group Vice , Drug Administration , Health Services Research , Outcomes Research , Takeda Pharmaceutical Company , Millennium Pharmaceuticals Inc , Exchange Commission , Community Versus Academic Practice In Essential Thrombocythemia , European Union , Takeda Pharmaceuticals International , American Society , Hematology Annual Meeting , Group Vice President , Oncology Targeted Therapeutics , Refractory Marginal Zone Lymphoma , Primary Analysis , Targeted Therapy ,